














































Autophagy is an essential process by which eukaryotic 
cells turn over long-lived cytosolic components, clear 
damaged proteins and organelles, and maintain bio-
energetic requirements during conditions of nutrient and 




























































































of cellular components can involve the uptake of small 
amounts of cytoplasm at the vacuole or lysosome 
surface (microautophagy) or, in response to a strong 
stimulus such as starvation, the formation of specialized 
double membraned-organelles termed autophagosomes, 
which engulf larger portions of cytoplasm or organelles 
before fusing with a vacuole or lysosome (macro-auto- 
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While this process is an important part of the normal 
balance between anabolic and catabolic processes and 
can prolong survival during nutrient limitation, 
autophagy is also an alternate death pathway that 
facilitates type II programmed cell death [4-6]. For this 
reason, imbalances in this pathway can contribute 
to seemingly diverse pathologies. 
 
Resveratrol is a small polyphenol that extends the 
lifespan of simple model organisms, ostensibly by 
mimicking caloric restriction [7, 8]. In rodents, 
resveratrol protects from a variety of age-related diseases 
including cancer, cardiovascular disease, neurodegenera-
tion, obesity and diabetes [9-14]. Although there is 
evidence that some of resveratrol’s actions are mediated 







































underlying the numerous beneficial effects of 
resveratrol remain to be elucidated. 
 
It has previously been reported that 24-48 hours of 
resveratrol treatment induces autophagy in cancer cells 
grown in rich media, suggesting a mechanism by which 
resveratrol might enhance cell death and suppress tumor 
growth [15-18]. Here we report the effect of resveratrol 
treatment on the normal induction of autophagy over 4-6 
hours following nutrient withdrawal in tumor and non-
tumor cell lines. In contrast to the activation of the 
autophagic pathway observed in tumor cells in complete 
media, we find that resveratrol markedly inhibits the 
starvation-induced autophagic response. We show that 
this effect does not require SIRT1, and identify p70 S6 
kinase (S6K1) as a target of resveratrol that is responsible 













































at 40X magnification are shown. (D) Quantification was performed on HEK293 cells as in (B). Error bars represent s.e.m. * (p < 0.0022). 
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Suppression of nutrient starvation- and rapamycin-
induced autophagy by resveratrol 
 
Autophagy is an important component of the cellular 
response to nutrient stress and growth factor withdrawal. 
We therefore tested whether resveratrol treatment would 
influence regulation of autophagy under these conditions. 
Autophagy was assessed by monitoring the relocalization 
of a component of the autophagy machinery, LC3, from 
the cytoplasm to the forming autophagosome [19]. 
NIH/3T3 cells or HEK293 cells stably expressing a GFP-
LC3 fusion protein were generated and were induced to 
undergo autophagy in the presence or absence of 
resveratrol. Treatment with resveratrol resulted in a 
dramatic reduction in the number of starvation-induced 
GFP-LC3 punctae (Figure 1). Similar inhibitory effects 
on autophagy were observed in other cell lines, including 
human tumor cell lines (HeLa and U2OS), as well as 
mouse embryonic fibroblasts (MEFs) using mono-
dansylcadaverine (MDC), a fluorescent compound that 
stains late autophagosomes (Supplementary Figures S1 
and S3) [20]. Since previous studies have described an 
increase in autophagy following 24 hours of resveratrol 





























of resveratrol under these conditions. Consistent with 
these results, we observed an induction of auto-
phagosome formation in cells treated with resveratrol 
for 24 hours in complete media containing serum 
(Supplementary Figure S2). Thus, the influence of 
resveratrol on autophagy is context dependent, and in 
the case of autophagy induced by nutrient limitation, 
resveratrol is inhibitory. 
 
Rapamycin is an inhibitor of the nutrient sensing 
mTOR-Raptor complex and has been shown to induce 
autophagy [21, 22]. In yeast, it had been shown that 
resveratrol can reverse some markers of autophagy 
induced by rapamycin [23]. Consistent with these 
results and similar to the results seen under nutrient 
limitation, rapamycin-induced autophagy is almost 
completely abrogated by resveratrol treatment (Figure 
2A and B). Decreased GFP-LC3 punctae could be due 
either to increased flux or a block in autophagy. To 
distinguish between these two possibilities, we 
examined LC3-II accumulation with and without 
Bafilomycin A1, an inhibitor of lysosome degradation. 
Under both conditions, resveratrol was able to block the 
accumulation of LC3-II, indicating a suppression of 
autophagy rather than an enhancement of lysosomal 















































































W e  n e x t  t e s t e d  w h e t h e r  S I R T 1 ,  a n  N A D
+-dependent 
deacetylase that is activated by resveratrol [8], was 
required for this effect. To test this hypothesis, HEK 
293 GFP-LC3 cells were transfected with either control 
siRNA or an siRNA directed against the SIRT1 
deacetylase and subsequently nutrient starved in the 
presence or absence of resveratrol. We found that both 
control and SIRT1 knockdown cells displayed a similar 
level of induction of GFP-LC3 punctae and that 
resveratrol still produced an equivalent suppression of 
autophagy (Figure 3). Consistent with these results, 
SIRT1+/+ and SIRT1-/- MEFs induced autophagy in 
response to nutrient withdrawal, and in both cell lines 
the inhibitory effect of resveratrol on autophagy was 















































cate that inhibition of starvation-induced autophagy by 
resveratrol is molecularly distinct from the induction 
seen in previous studies and is not mediated by the 
SIRT1-dependent pathway that has previously been 
described [24]. It will be interesting to explore the 
differences in these systems that engage or disengage 
SIRT1 during autophagic induction. 
 
Kinase profiling of resveratrol in vitro 
 
Resveratrol has previously been shown to inhibit 
several kinases including PKC and Src [25] and is 
structurally similar to the flavanoid quercetin (Figure 
4A), which is an inhibitor of PI 3-kinase [26]. 
Therefore, we hypothesized that the effect of resveratrol 
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more upstream kinases. To test this, we performed an in 
vitro kinase screen and determined an inhibition profile 
for resveratrol. Out of 100 kinases tested, Jak2, NLK, 
p70 S6 kinase (S6K1), Pim-1, and Pim-2 emerged as 
potential targets of resveratrol (Figure 4B, Sup-
plementary Table 1). With the exception of S6K1, these 
kinases play primary roles in the hematopoietic system, 
and were thus viewed as unlikely to have been 
responsible for the effect we were studying. Further-
more, although JNK had previously been shown to play 
a positive role in autophagy, its activity was not 
significantly inhibited by resveratrol at this dose [27]. 










































role in the regulation of autophagy in Drosophila [28], 
making it a promising candidate for the in vivo target of 
resveratrol that is responsible for inhibition of auto-
phagy. 
 
To confirm the inhibition of S6 kinase by resveratrol in 
vitro, we determined the effect of the compound on 
immunoprecipitated HA-tagged S6K1 from HEK293 
cells using purified GST-tagged full-length recombinant 
S6 ribosomal protein (S6) as a substrate. In agreement 
with the primary screen, we found that resveratrol 
inhibited the activity of S6 kinase in a dose-dependent 
manner, exhibiting an IC50 of ~25 μM (Figure 4C and 







































































Resveratrol-mediated inhibition of S6 kinase activity 
in vivo 
 
To test whether resveratrol alters S6 kinase activity in 
cells, we treated NIH/3T3 and HEK293 cells with 
resveratrol and analyzed the phosphorylation status of 
S6, a well-characterized downstream target of S6 
kinase. After 30 minutes, phosphorylation of S6 was 
dramatically decreased in a dose-dependent manner in 
both cell lines at concentrations consistent with the 
IC50 determined in vitro (Figure 5A). These results 
were observed in a variety of different mammalian cell 
lines and were independent of SIRT1, since treatment of 
either SIRT1-/- or wildtype MEFs with resveratrol 
resulted in a similar decrease in S6 phosphorylation 
(Figure 5B). It is interesting to note that the doses 
required to inhibit phosphorylation of S6 were 
significantly higher in MEFs than those in other lines. 
Consistent with this observation, inhibition of 
autophagy in MEFs also required a higher concentration 
than in other cell lines (Supplementary Figure S3). 
 
Regulation of starvation-induced autophagy by S6 
kinase 1 
 
To test whether inhibition of S6K1 might account for 
suppression of autophagy by resveratrol, GFP-LC3 
expressing HEK293 cells were infected with retrovirus 
encoding a dominant-negative (K100R) mutant of S6 
kinase 1 or lentivirus encoding an shRNA against 
human S6K1. Cells expressing K100R S6K1 or 
knocked down for S6K1 expression showed a 
significant reduction in the number of GFP-LC3 
punctae compared to control cells following nutrient 
























kinase inhibition is sufficient to suppress the induction of  
autophagy under nutrient-starved conditions. Similar 
observations have been made previously in Drosophila 
[28], but had not been extended to mammalian systems. 
Mieulet et al. have observed that a normal basal level of 
autophagy still proceeds in S6K1;S6K2-/- muscle cells 
[29]; however, it is not clear whether nutrient deprivation 
or rapamycin can induce an increase in autophagy in this 
system. Moreover, studies in these mice suggest that 
mitogen signaling through p90rsk might compensate for 
the loss of S6 kinase signaling [30]. Our results support 
the view that under normal circumstances S6K1 plays a 
role in the induction of autophagy in response to nutrient 
deprivation. 
 
S6 kinase dependence of resveratrol-mediated 
suppression of autophagy 
 
To provide additional evidence that the effects of 
resveratrol are mediated via S6K1, HEK293 cells 
infected with control virus or a virus encoding shRNA 
against S6K1 were treated with resveratrol and 
subjected to nutrient withdrawal. Individually, S6K1 
shRNA and resveratrol both dramatically reduced the 
number of GFP-LC3 punctae, and resveratrol treatment 
in the absence of S6K1 produced no further decrease 
(Figure 7A). Quantification of punctae revealed no 
statistically significant difference between any of the 
experimental treatments, all of which were significantly 
different when compared to control cells (Fig 7B). 
These data indicate that S6 kinase is required for the full 
induction of autophagy in response to nutrient 
withdrawal in mammals, and lend further support to the 
view that the reduced level of autophagy in resveratrol-
treated cells is due to inhibition of S6K1. 
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Resveratrol has been characterized as an activator of 
SIRT1/Sir2, which are members of a family of enzymes 
that promote longevity in lower organisms [7, 8, 31-33]. 
In rodents, resveratrol has many beneficial effects 
including cancer prevention, cardio- and neuroprotective 
effects, and improvements in insulin sensitivity, although 
the extent to which these effects are mediated by SIRT1 
is not yet clear [9-14]. Here we identify a novel target of 
resveratrol activity, S6K1, that may have important 
implications for understanding the mechanisms by which 
resveratrol increases health in both lower organisms and 
mammals. We suggest that inhibition of S6K1 may act in 
parallel to or in concert with activation of SIRT1 to 
modulate lifespan and health. 
 
A previous study described an important positive role 
for SIRT1 in autophagy; however, we did not observe a 
noticeable change in the rate of autophagy when 
altering SIRT1 activity in various assays. It was 
recently shown that FK866, a NAMPT inhibitor, leads 
to reduced NAD
+ and is sufficient to induce autophagy. 
This suggests that SIRT1 was also not required to 
induce autophagy, since NAD
+ is required for SIRT1 
activity [34]. It will be important to understand the 
differences in these studies in order to clarify under 
what conditions SIRT1 can regulate autophagy. 
 
The role of S6K in autophagy has generated 
considerable confusion due to seemingly conflicting 
data. Inhibition of the upstream kinase, mTOR, induces 
autophagy [3] and accordingly, ribosomal protein S6 
phosphorylation has been inversely correlated with 
autophagy [35]. In addition, ATG1 has been shown to 
inhibit S6 kinase activity by blocking its ability to be 
phosphorylated on Thr 389 [36]. However, in 
Drosophila, S6 kinase is required for induction of 
autophagy in response to starvation or genetic 
manipulation of the insulin-signaling pathway [28]. 
These data suggest that under some conditions, mTOR 
and S6K can oppose each other or that S6K may be 
activated in an mTOR independent manner. Consistent 
with the work on Drosophila S6K, our data support a 
positive role for S6K1 in autophagic induction in 
mammals, and raise important questions about how this 
could occur. It is reasonable to envisage the existence of 
a novel substrate of mammalian S6 kinase that is 
required for initiation or maturation of autophagic 
vesicles, which is targeted only in the absence of mTOR 
activity, and that this target’s phosphorylation may be 
required for autophagy to proceed. This mechanism 
would provide a dual switch for the initiation of 
autophagy, facilitating tighter control of a process that 
has both positive and negative implications for the cell. 
 
It is interesting to consider why resveratrol treatment 
might have an inhibitory effect on starvation-induced 
autophagy, yet stimulate the inappropriate induction of 
autophagy in nutrient rich media. One possibility is that 
insulin signaling is the key difference. Under nutrient 
withdrawal, where insulin signaling is minimal, 
inhibition of S6K1, leading to a reduction in autophagy, 
might be the dominant effect of resveratrol. On the 
other hand, when autophagy is held in check by robust 
signaling through insulin-PI3K-Akt-mTOR (fed 
conditions), disrupting this pathway might lead to the 
induction of autophagy over time. It will be interesting 
to test the effects of resveratrol on autophagy in 
animals, especially under starvation or tumor models, 
where we might observe a similar duality of function. 
 
Negative regulation of homologs of S6 kinase in lower 
organisms promotes beneficial effects on health and 
lifespan. In yeast, deletion of Sch9, the homolog of 
mammalian S6K/Akt, protects against age-dependent 
defects in a yeast model of aging and cancer and 
extends chronological lifespan [37-39]. In Drosophila it 
has previously been shown that expression of a 
dominant negative S6K can extend lifespan [40] and 
results in increased resistance to oxidative stress [41]. 
Resveratrol’s effects on lifespan and resistance to 
oxidative stress are well established; therefore, it would 
be exciting if some of these effects are due to 
suppression of S6K activity. 
 
Of considerable interest is the fact that resveratrol-
treated mice exhibit most of the phenotypes of S6K1-/- 
mice when fed a high fat diet [12, 13, 42]. In 
comparison to control animals, both resveratrol treated 
and S6K1-/- mice have significantly less body fat and 
their peripheral tissues remain highly sensitive to 
insulin. Moreover, mitochondrial number and activity 
are increased in both S6K1-/- and resveratrol-treated 
mice. It is therefore interesting to speculate that 
resveratrol’s ability to modulate S6K1 activity might be 
responsible for at least some of the therapeutic effects 
observed in recent studies. 
 
A major unanswered question is how resveratrol can 
mediate protection from a diverse range of disease 
processes such as cancer, neurodegenerative disease, 
and liver disease. One possible explanation proposed by 
Howitz and Sinclair to explain these effects is the 
Xenohormesis Hypothesis [8, 43]. The theory proposes 
that organisms have adapted to sense stress-induced 
molecules produced by other species in their 
environment, and use these cues to induce a protective 
response in preparation for adversity. This may explain 
why many stress-induced phytochemicals, such as 
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for health and seem to act through multiple pathways 
[9]. In the case of resveratrol, this includes SIRT1 
activation, inhibition of cyclooxygenase and NFκB, 
induction of antioxidant enzymes, and activation of 
AMPK in vivo [13, 44], in addition to the inhibition of 
the leukemia-related kinases and S6K1 reported here 
(Supplementary Table 1). 
 
Taken together, these results suggest that the 
requirement for S6 kinase in autophagy is evolutionarily 
conserved from flies to mammals. Our observation that 
S6K1 is necessary to achieve full induction of 
autophagy in response to nutrient withdrawal opens the 
door to future studies to discover downstream targets of 
S6K1 that may be important regulators of autophagy. 
Furthermore, we establish S6 kinase as a novel target 
for resveratrol action which may play an important role 
in mediating its beneficial effects on disease processes 




Cell Lines, Lysates, and Antibodies. HEK293, 
HEK293T, U2OS, HeLa, NIH/3T3, and mouse 
embryonic fibroblast cells were maintained in DMEM 
(GIBCO, Carlsbad, CA) +10% FBS (Gemini Bio-
Products, West Sacramento, CA) + 100 units/ml 
penicillin/100  μg/ml streptomycin (GIBCO, Carlsbad, 
CA) +2mM glutamine (GIBCO, Carlsbad, CA) at 37 ºC 
+5% CO2. SIRT1+/+ and SIRT1-/- MEFs were a gift 
from K. Chua, R. Mostoslavsky, and F. Alt (Harvard 
Medical School, Boston, MA). HEK293 cells stably 
expressing GFP-LC3 were maintained in media 
supplemented with 2 mg/ml puromycin (InvivoGen, 
San Diego, CA). For S6 phosphorylation experiments, 
cells were grown overnight and were subjected to 
various doses of resveratrol (LALILAB Inc, Durham, 
NC) or DMSO control for the indicated times. Cells 
were subsequently washed once in PBS and lysed in ice 
cold PBS +0.5% NP-40 (Sigma Aldrich, St. Louis, MO) 
+ Complete Mini EDTA-free protease inhibitor tablet 
(Roche, Basel, Switzerland) + 1:100 phosphatase 
inhibitor cocktail 1 (Sigma Aldrich, St. Louis, MO). 
Following normalization of protein by Bradford assay 
(Bio-Rad, Hercules, CA), samples were resolved by 
SDS-PAGE and western blotted with the indicated 
antibodies. Antibodies for p70 S6 kinase, Phospho-S6 
ribosomal protein (Ser240/244), S6 ribosomal protein, 
and total Erk antibodies were obtained from Cell 
Signaling Technology (Beverley, MA). Polyclonal HA 
antibody was obtained from Sigma Aldrich (St. Louis, 
MO). Monoclonal β-tubulin antibody was obtained 
from Upstate (Lake Placid, NY). Monoclonal antibody 
for GAPDH was obtained from Abcam (Cambridge, 
MA). Anti-LC3 peptide-based polyclonal antibody was 
a gift from J. Brugge (Harvard Medical School, Boston, 
MA). 
 
Plasmids, RNAi, and Virus Infection. The plasmids 
pBABE HA-S6K1 K100R, pRK7 HA-S6K1 wt, pRK7 
HA-S6K1 K100R, and pGEX-GST-S6 were gifts from 
J. Blenis (Harvard Medical School, Boston, MA). 
Lentiviral based shRNAs directed against S6K1 were 
obtained from B. Hahn and The RNAi Consortium 
(Harvard Medical School/Broad Institute). pBABE-
GFP-LC3 was a gift from J. Debnath (Harvard Medical 
School, Boston, MA). RISC-free control siRNA and 
SIRT1 specific siGENOME siRNA (D-003540-05) 
(Dharmacon, Chicago, IL) were transfected with 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) 
according to manufacturer’s specifications. The shRNA 
sequence used for human S6K1 was (AGCACAGCAA 
ATCCTCAGACA). Retrovirus and lentivirus were 
generated by transient transfection of HEK293T cells 
with packaging plasmids and the target plasmid using 
polyethyleneimine (PEI). Virus was harvested 48 and 
72 hours post-transfection. For disruption of S6K1 
function in GFP-LC3 expressing HEK293 cells, cells 
were infected with retrovirus encoding S6K1 K100R or 
lentivirus encoding an shRNA directed against S6K1. 
Cells were assayed for autophagy and protein 
expression three days after infection. 
 
Autophagy Assays. For autophagy studies, GFP-LC3 
expressing cells were plated overnight on coverslips. In 
the case of HEK293 cells glass coverslips were pre-
coated with a solution of 0.1 mg/ml poly-ornithine 
(Sigma Aldrich, St. Louis, MO) to aid in attachment. 
Cells were washed twice with PBS and placed in either 
growth medium or starvation medium, Earle’s Balanced 
Salt Solution (Sigma Aldrich, St. Louis, MO) for the 
indicated times. In resveratrol experiments, cells were 
pretreated for 1 hour with either DMSO or resveratrol 
and then placed in starvation media or treated with 200 
nM rapamycin (Calbiochem, San Diego, CA) ± 
resveratrol (where indicated). The dose of resveratrol 
used to assay autophagy was 50 μM unless otherwise 
indicated. Following treatment cells were fixed in 3.7% 
paraformaldehyde (Sigma Aldrich, St. Louis, MO) and 
mounted with GEL/MOUNT (Biomedia corp., Foster 
City, CA). Cells were then visualized on a Zeiss 
Axiovert with a 63X oil immersion lens and digital 
photomicrographs were captured with a CCD camera. 
To quantify GFP-LC3 punctae, at least 4 random fields 
were imaged and the average number of punctae/cell 
was calculated. Data sets were compared using 
Student’s t- Test (two-tailed assuming equal variance). 
For autophagosome staining of SIRT1-/- or SIRT1+/+ 
MEFs, U2OS, or HeLa, the cells were treated as 
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30  μM monodansylcadaverine (Sigma Aldrich, St. 
Louis, MO) in the media for 10 minutes at 37ºC +5% 
CO2 and then fixed with 3.7% paraformaldehyde and 
visualized as described. For the LC3 flux assay, 
HEK293 GFP-LC3 cells pretreated with 50 μM 
resveratrol for 1 hour followed by treatment with either 
DMSO or 1 mM rapamycin (Calbiochem, San Diego, 
CA) in the presence or absence of 100 nM bafilomycin 
A1 (Sigma Aldrich, St. Louis, MO). Cells were washed 
once in 4ºC PBS and immediately lysed in 2X Lammeli 
sample dye and then boiled for 10 minutes. Samples we 
subsequently run on a 15% polyacrylamide gel and 
western blotted for LC3 and tubulin. LC3-II/tubulin 
ratios we quantified with ImageJ (NIH). 
 
Kinase Profile and Kinase Assay. A Kinase profile 
against 100 kinases listed for resveratrol at 20 μM was 
generated utilizing Upstate’s KinaseProfiler™ service. 
Assay protocols for each kinase are available from 
Upstate (Lake Placid, NY). In vitro kinase assay was 
performed as described previously [45]. Briefly, 
HEK293 cells were transfected with HA-S6K1 wt, HA-
S6K1 K100R, or vector as indicated. Cells were treated 
with 1 μg/ml insulin for 10 minutes prior to harvesting 
in PBS + 0.5% NP-40 + protease and phosphatase 
inhibitors. 125 μg of lysate per sample was immuno-
precipitated using 0.5 μg/sample of anti-HA High-
Affinity (Roche, Basel Switzerland). Beads from 
immunoprecipitations were washed three times in lysis 
buffer and once in kinase buffer, and kinase assays were 
performed with recombinant GST-S6 as substrate (1 μg 
per assay). In the indicated lanes varying doses of 
resveratrol or DMSO control were added to the reaction 
prior to addition of the GST-S6 substrate. All samples 
were subjected to SDS-PAGE, and 32P incorporation 
was quantified by using a Bio-Rad (Hercules, CA) 
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No  Kinase  Activity (% of Control)    No  Kinase  Activity ( % of Control) 
1  Abl(h)  105 ± 7    51  MST2(h)  73 ± 8 
2  Abl(T315I)(h)  100 ± 2    52  NEK2(h)  102 ± 4 
3  ALK(h)  39 ± 0    53  NEK3(h)  96 ± 8 
4  ALK4(h)  110 ± 3    54  NEK6(h)  140 ± 16 
5  AMPK(r)  39 ± 2    55  NEK7(h)  116 ± 2 
6  Aurora-A(h)  65 ± 1     56  NLK (h)  30 ± 2 
7  CDK1/cyclinB(h)  67 ± 3    57  p70S6K(h)  21 ± 1 
8  CDK2/cyclinA(h)  80 ± 1    58  PAK2(h)  98 ± 4 
9  CDK2/cyclinE(h)  80 ± 0    59  PAK3(h)  46 ± 0 
10  CDK3/cyclinE(h)  75 ± 4    60  PAK4(h)  103 ± 4 
11  CDK5/p25(h)  64 ± 4     61  PAK6(h)  103 ± 3 
12  CDK5/p35(h)  77 ± 2    62  PDGFRα(h)  114 ± 2 
13  CDK6/cyclinD3(h)  55 ± 2    63  PDGFRß(h)  119 ± 2 
14  CDK7/cyclinH/MAT1(h)  95 ± 1    64  PDK1(h)  108 ± 7 
15  CDK9/cyclin T1(h)  70 ± 3    65  PI 3-Kinaseβ(h)  107 ± 1 
16  CHK1(h)  95 ± 2    66  PI 3-Kinaseγ(h)  101 ± 1 
17  CHK2(h)  59 ± 6    67  PI 3-Kinaseδ(h)  106 ± 1 
18  cKit(h)  68 ± 0    68  Pim-1(h)  6 ± 2 
19  CSK(h)  94 ± 5    69  Pim-2(h)  14 ± 2 
20  cSRC(h)  61 ± 1    70  PKA(h)  100 ± 0 
21  DAPK1(h)  71 ± 3    71  PKBα(h)  94 ± 2  
22  DAPK2(h)  67 ± 7    72  PKBß(h)  105 ± 3 
23  EGFR(h)  90 ± 5    73  PKBγ(h)  89 ± 4 
24  EphB2(h)  113 ± 1    74  PKCα(h)  114 ± 9 
25  FGFR1(h)  58 ± 2    75  PKCßI(h)  103 ± 5 
26  Fgr(h)  78 ± 5    76  PKCγ(h)  80 ± 8 
27  Flt1(h)  52 ± 1    77  PKCδ(h)  92 ± 1 
28  Flt3(h)  41 ± 1    78  PKCθ(h)  99 ± 5 
29  Fms(h)  61 ± 2    79  PKCζ(h)  89 ± 0 
30 GSK3α(h)  79 ± 4    80  PKD2(h)  88 ± 5 
31  GSK3ß(h)  92 ± 0    81  PKG1ß(h)  56 ± 4 
32  IGF-1R(h)  75 ± 0    82  Plk3(h)  95 ± 9 
33 IKKα(h)  40 ± 1    83  Ros(h)  102 ± 4 
34  IKKß(h)  116 ± 2    84  Rsk1(h)  70 ± 1 
35  IR(h)  71 ± 5    85  Rsk2(h)  32 ± 0 
36  IRR(h)  40 ± 0    86  SAPK2a(h)  100 ± 4  
37  IRAK1(h)  97 ± 0    87  SAPK2a(T106M)(h)  102 ± 2 
38  JAK2(h)  27 ± 5    88  SAPK2b(h)  100 ± 1 
39 JNK1α1(h)  89 ± 5    89  SAPK3(h)  110 ± 5 
40 JNK2α2(h)  110 ± 4    90  SAPK4(h)  92 ± 4 
41  JNK3(h)  98 ± 3    91  SGK(h)  86 ± 13 
42  LIMK1(h)  84 ± 4    92  SGK2(h)  70 ± 1 
43  LKB1(h)  102 ± 3    93  SIK(h)  76 ± 1 
44  MAPK1(h)  94 ± 13    94  Snk(h)  81 ± 3 
45  MAPK2(h)  101 ± 10    95  TAK1(h)  105 ± 3 
46  MEK1(h)  110 ± 5    96  TBK1(h)  62 ± 4 
47  Met(h)  114 ± 5    97  Tie2(h)  94 ± 8 
48  MSK1(h)  58 ± 1    98  TrkA(h)  31 ± 3 
49  MSK2(h)  60 ± 1    99  TrkB(h)  98 ± 1 
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Supplementary Figure S1. Resveratrol inhibits
nutrient‐starvation  induced  autophagy  in
multiple cell lines. (A) MDC staining of U2OS cells
subjected to nutrient limitation (Starved) ± 50 μM





Supplementary  Figure  S2.  Long‐term
resveratrol  treatment  induces  autophagy  in
rich  media.  (A)  HEK293  GFP‐LC3  expressing  cells
incubated  in  complete  media  plus  serum  were
subjected to 50 or 100 μM resveratrol for 24 hours.
(B)  HEK293  GFP‐LC3  cells  were  treated  with  EBSS
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Supplementary Figure S3. Resveratrol mediat‐
ed inhibition of autophagy is independent of
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